Tag: invikafusp_alfa
-
Experimental T-Cell Therapy Invika Halts Progression of Treatment-Resistant Tumors in Early Trial
NIH-led phase 1/2 trial finds invikafusp alfa, a precision T-cell therapy, halted disease progression in 59.3% of patients with immunotherapy-resistant solid tumors and shrank tumors in four.
HealthScience & TechnologyMedical ScienceLegalBusiness invikafusp alfaNational Institutes of HealthNational Cancer Instituteimmunotherapyclinical trialcolorectal cancerMarengo Therapeutics